Our data adds to the increasing evidence that MAPK pathways modulate GC response in ALL cells and, more recently, anisomycin, a protein synthesis inhibitor and p38 (also termed MAPK14) agonist, was shown to resensitize GC response via activation of both p38 and JNK (Miller et al, 2007; Garza et al, 2009; Liu et al, 2013). The gene discussed is MAPK8; the disease is acute lymphoblastic leukemia.